Canada Abandons Controversial Drug Pricing Reforms Following Court Ruling
核心洞察
The Canadian government announced it will no longer implement controversial amendments to drug pricing regulations, including economic factors and net price reporting requirements, following a Quebec Court of Appeal ruling that deemed these measures unconstitutional.
Health Canada will proceed with implementing a new basket of international price comparator countries (PMPRB11) and reduced reporting requirements for low-risk medicines, effective July 1, 2022.
The decision represents a significant victory for the pharmaceutical industry in Canada, potentially reducing regulatory burden while maintaining some price control measures through the updated international reference basket.
The Canadian government has announced it will abandon controversial drug pricing reforms following a court ruling that found key amendments unconstitutional, marking a significant shift in the country's pharmaceutical regulatory landscape.
Health Canada declared it will no longer pursue implementation of amendments related to economic drug price regulatory factors or requirements for manufacturers to report net prices. The decision follows the Quebec Court of Appeal's ruling in Merck Canada (搜索) inc. c. Procureur general du Canada, 2022 QCCA 240, which found that proposed amendments adding new economic factors to assess excessive drug pricing were unconstitutional.
Regulatory Changes Moving Forward
Despite abandoning the controversial elements, Health Canada will implement a revised basket of international price comparator countries, transitioning from the current PMPRB7 to PMPRB11. The new reference basket will include Australia, United Kingdom, Belgium, France, Germany, Italy, Japan, Netherlands, Norway, Spain, and Sweden, removing the United States and Switzerland from consideration.
The government will also proceed with reduced reporting requirements for medicines at lowest risk of excessive pricing, including vaccines and biosimilars. These changes are scheduled to take effect July 1, 2022.
Impact on Drug Pricing
Analysis of the reference basket change suggests significant implications for new drug launches in Canada. Research examining four case study medicines across various therapeutic areas found that ceiling prices would decrease by 5-11% under the new PMPRB11 reference basket compared to the previous PMPRB7 system.
The removal of the United States and Switzerland from the reference basket is expected to substantially lower price ceilings, as these were the highest and third-highest priced countries in the OECD region in 2019. For newly launching products, the overall price ceiling is likely to be significantly lower under the new guidelines.
Existing products may face less price pressure than new launches, except in cases where significant price differentials exist between Canada and other markets. Products that have experienced price decreases after indication expansion or delisting in other countries may be particularly affected.
Industry Implications
The decision represents what industry observers describe as an important victory for pharmaceutical companies operating in Canada. Canadian appeal courts have signaled that general price control and consumer protection fall outside the PMPRB (搜索)'s jurisdiction and are not part of the balance established in the Patent Act between incentivizing research and development and protecting against patent abuse.
From a manufacturer perspective, the original comprehensive reforms had raised concerns about deprioritized investment in the Canadian market. Companies had been considering strategies to mitigate negative impacts, including delayed launches, launching without patents, or avoiding the Canadian market entirely.
Healthcare System Effects
The PMPRB (搜索) guideline updates may drive changes to existing pricing and market access processes within the Canadian healthcare system. The reforms could potentially affect the roles of existing health technology assessment agencies, CADTH (搜索) and INESSS (搜索), which currently execute clinical and economic evaluations to inform reimbursement decisions.
The changes come as public health plans face budget pressures following the COVID-19 pandemic. While the PMPRB (搜索) reforms may offer some relief in terms of reducing spending on new medicines through lower list prices, this comes alongside concerns about decreased confidence and investment in the Canadian pharmaceutical market.
Industry experts suggest that innovative access agreements, including payment-by-results and value-based arrangements, may provide options for manufacturers to manage net price discounting while securing patient access to new medicines.